X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
Status:
Recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered
to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be
positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).